Compare · ARGX vs PLUR
ARGX vs PLUR
Side-by-side comparison of argenx SE (ARGX) and Pluri Inc. (PLUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and PLUR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $58.42B, about 4416.9x PLUR ($13.2M).
- PLUR has been more active in the news (9 items in the past 4 weeks vs 6 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 0 for PLUR).
- Company
- argenx SE
- Pluri Inc.
- Price
- -
- -
- Market cap
- $58.42B
- $13.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 6
- 9
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
- Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
- Amendment: SEC Form SCHEDULE 13G/A filed by argenx SE
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
- argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
- SEC Form 6-K filed by argenx SE
Latest PLUR
- SEC Form SCHEDULE 13G filed by Pluri Inc.
- Pluri CEO Letter: Turning Our Cell Technology and Experience into Commercial Opportunity
- Amendment: SEC Form S-3/A filed by Pluri Inc.
- SEC Form 10-Q filed by Pluri Inc.
- Pluri Adds ISO 9001 and ISO 13485 Certifications to Support PluriCDMO Commercial Expansion
- Pluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments
- Director Manieu Alexandre Weinstein bought $1,250,001 worth of shares (833,334 units at $1.50) (SEC Form 4)
- Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
- Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company